Vasculitis & polymyalgia rheumatica
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
An erratum to this article was published (Arthritis Rheumatol, Aug 2026 ↗)
Authors' conclusion
In patients with relapsing, nonsevere GPA, abatacept did not reduce the risk of relapse, severe worsening, or failure to achieve remission.
Study context
- Population
- Patients with relapsing, nonsevere granulomatosis with polyangiitis (GPA); those on MTX, AZA, mycophenolate or LEF continued at a stable doserandomized
- Participants
- 65 patients
- Comparison
- Abatacept 125 mg SC weekly vs placebo, both with prednisone 30 mg/day tapered and discontinued at week 12
- Abataceptn = 34
- Placebon = 31reference
- Primary endpoint
- Rate of treatment failure: relapse, disease worsening, or failure to achieve BVAS/WG of 0 or 1 by 6 months
- Follow-up
- Six months
Methodological detailsdouble-blind, placebo-controlled, multicentre, Patients not in remission by month 6, or with nonsevere relapse or worsening, could receive open-label abatacept
- Double-blind
- Placebo-controlled
- Multicentre
- Patients not in remission by month 6, or with nonsevere relapse or worsening, could receive open-label abatacept
Primary result
As reported in the abstract
Treatment failure rate
- No statistical difference in treatment failure rate between abatacept and placebo
- Abatacept vs Placebo: P = 0.853
Secondary outcomes
Key secondary end points: time to full remission (BVAS/WG = 0), duration of GC-free remission, relapse severity, prevention of damage, patient-reported quality of life
- No statistical difference between abatacept and placebo
Original publication
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis. Arthritis Rheumatol. Published 15 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →